Monkeypox in humans : a new outbreak
©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)..
Infection caused by Monkeypox Virus (MPVX) has small rodents as its natural reservoir and both monkeys and humans are occasional hosts. The causative agent is an Orthopoxvirus (MPVX) that was isolated in monkeys in 1958 and proved capable of passing to humans in 1970. It remained contained in Africa, causing isolated episodes of infection, until 2003 when an outbreak occurred in the United States following importation of animals from that continent. Since then, anecdotal cases have continued to be reported outside Africa, usually very clearly linked to travelers to those countries, but in May 2022, a broad outbreak of this disease has begun, now affecting several continents, with the emergence of human cases of MPVX (H-MPVX) infection mainly among Men that have Sex with Men (MSM). The disease has an incubation time ranging from 5 to 15 days and is characterized by the presence of pustules, fever, malaise and headache. The presence of significant regional lymphadenopathy is a differential feature with episodes of classical smallpox. Proctitis and pharyngitis, with minimal skin lesions, may be another form of presentation. Diagnosis can be confirmed by PCR testing of lesions or by demonstration of MPVX in other body fluids or tissues, although in the appropriate epidemiologic setting the clinical picture is highly suggestive of the disease. Effective drug treatment has been developed as part of programs to protect against potential bioterrorist agents and smallpox vaccinees are known to have high protection against monkeypox. New vaccines are available, but neither the drugs nor the vaccines are yet freely available on the market. The prognosis of the disease appears, at least in adults in developed countries, to be good, with very low mortality figures and much less aggressive behavior than that described in classical smallpox. Isolation measures, essential for the control of the outbreak, have been published by the health authorities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 35(2022), 6 vom: 08. Dez., Seite 509-518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martín-Delgado, M C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 30.11.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/059.2022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343067013 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343067013 | ||
| 003 | DE-627 | ||
| 005 | 20231227130836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.37201/req/059.2022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM343067013 | ||
| 035 | |a (NLM)35785957 | ||
| 035 | |a (PII)martin06jul2022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martín-Delgado, M C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monkeypox in humans |b a new outbreak |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). | ||
| 520 | |a Infection caused by Monkeypox Virus (MPVX) has small rodents as its natural reservoir and both monkeys and humans are occasional hosts. The causative agent is an Orthopoxvirus (MPVX) that was isolated in monkeys in 1958 and proved capable of passing to humans in 1970. It remained contained in Africa, causing isolated episodes of infection, until 2003 when an outbreak occurred in the United States following importation of animals from that continent. Since then, anecdotal cases have continued to be reported outside Africa, usually very clearly linked to travelers to those countries, but in May 2022, a broad outbreak of this disease has begun, now affecting several continents, with the emergence of human cases of MPVX (H-MPVX) infection mainly among Men that have Sex with Men (MSM). The disease has an incubation time ranging from 5 to 15 days and is characterized by the presence of pustules, fever, malaise and headache. The presence of significant regional lymphadenopathy is a differential feature with episodes of classical smallpox. Proctitis and pharyngitis, with minimal skin lesions, may be another form of presentation. Diagnosis can be confirmed by PCR testing of lesions or by demonstration of MPVX in other body fluids or tissues, although in the appropriate epidemiologic setting the clinical picture is highly suggestive of the disease. Effective drug treatment has been developed as part of programs to protect against potential bioterrorist agents and smallpox vaccinees are known to have high protection against monkeypox. New vaccines are available, but neither the drugs nor the vaccines are yet freely available on the market. The prognosis of the disease appears, at least in adults in developed countries, to be good, with very low mortality figures and much less aggressive behavior than that described in classical smallpox. Isolation measures, essential for the control of the outbreak, have been published by the health authorities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a MPVX | |
| 650 | 4 | |a Monkeypox | |
| 650 | 4 | |a Poxvirus | |
| 650 | 4 | |a outbreaks | |
| 650 | 4 | |a sexually transmitted infections | |
| 650 | 4 | |a smallpox | |
| 650 | 4 | |a vaccines | |
| 700 | 1 | |a Martín Sánchez, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Sellés, M |e verfasserin |4 aut | |
| 700 | 1 | |a Molero García, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Guillén, S |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Artalejo, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Galiana, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cantón, R |e verfasserin |4 aut | |
| 700 | 1 | |a De Lucas Ramos, P |e verfasserin |4 aut | |
| 700 | 1 | |a García-Botella, A |e verfasserin |4 aut | |
| 700 | 1 | |a García-Lledó, A |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Sampelayo, T |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Pavón, J |e verfasserin |4 aut | |
| 700 | 1 | |a González Del Castillo, J |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, P |e verfasserin |4 aut | |
| 700 | 1 | |a Valerio, M |e verfasserin |4 aut | |
| 700 | 1 | |a Catalán, P |e verfasserin |4 aut | |
| 700 | 1 | |a Burillo, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cobo, A |e verfasserin |4 aut | |
| 700 | 1 | |a Alcamí, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bouza, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 35(2022), 6 vom: 08. Dez., Seite 509-518 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:6 |g day:08 |g month:12 |g pages:509-518 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/059.2022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 6 |b 08 |c 12 |h 509-518 | ||